A multidisciplinary team at Yale, led by Yale Cancer Center members, has defined a subgroup of genetic mutations that are present in a significant number of melanoma skin cancer cases. Their findings shed light on an important mutation in this deadly disease and may lead to more targeted anti-cancer therapies. The role of mutations in numerous genes and genomic changes in the development of melanoma is well established and continues to be the focus of intense research.
